Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer

Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis

(2021) Michal Sternschuss et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cell-programmed nutrient partitioning in the tumour microenvironment

(2021) Bradley I. Reinfeld et al.   NATURE

Tissue-Resident Memory-Like CD8+ T Cells Exhibit Heterogeneous Characteristics in Tuberculous Pleural Effusion

(2021) Sifei Yu et al.   Journal of Immunology Research

Immunotherapy in Breast Cancer: When, How, and What Challenges?

(2021) Beatriz Henriques et al.   Biomedicines

Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti–PD-L1 immunotherapy

(2020) Zhaoting Li et al.   Science Advances

Recent advances of two-dimensional materials in smart drug delivery nano-systems

(2020) Hua Zhang et al.   Bioactive Materials

Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer

(2020) Deanna N. Edwards et al.   JOURNAL OF CLINICAL INVESTIGATION

Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

(2019) Robert D. Leone et al.   SCIENCE

Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer

(2019) Rokaya El Ansari et al.   BRITISH JOURNAL OF CANCER

Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models

(2018) Michael L Schulte et al.   NATURE MEDICINE

Disruption of Amino Acid Homeostasis by Novel ASCT2 Inhibitors Involves Multiple Targets

(2018) Angelika Bröer et al.   Frontiers in Pharmacology

We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of6-Diazo-5-oxo-L-norleucine

(2018) Kathryn M. Lemberg et al.   MOLECULAR CANCER THERAPEUTICS

Emerging Cellular Therapies for Cancer

(2018) Sonia Guedan et al.   Annual Review of Immunology

Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism

(2018) Marc O. Johnson et al.   CELL

Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation

(2018) Vinicius Cruzat et al.   Nutrients

The Smart Drug Delivery System and Its Clinical Potential

(2016) Dong Liu et al.   Theranostics

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

(2016) Sasha E. Stanton et al.   JAMA Oncology

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

(2015) Steven J. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer

(2015) M van Geldermalsen et al.   ONCOGENE

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

(2014) M. D. Burstein et al.   CLINICAL CANCER RESEARCH

Concurrent interaction of DCs with CD4+and CD8+T cells improves secondary CTL expansion: It takes three to tango

(2014) Stefanie Hoyer et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Inflammatory T Cell Responses Rely on Amino Acid Transporter ASCT2 Facilitation of Glutamine Uptake and mTORC1 Kinase Activation

(2014) Mako Nakaya et al.   IMMUNITY